Jasgit C. Sachdev

8.7k citations
129 papers · 3.6k · 1 hit paper · h-index 24

Impact in

  • Cancer Research top 2%
    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research
  • Oncology top 1%
    • PARP inhibition in cancer therapy
    • Cancer Immunotherapy and Biomarkers

Papers in

  • Oncology 64
    • Cancer Treatment and Pharmacology 18
    • HER2/EGFR in Cancer Research 15
    • PARP inhibition in cancer therapy 12
    • Cancer Immunotherapy and Biomarkers 11
  • Molecular Biology 43
    • PI3K/AKT/mTOR signaling in cancer 10
Co-authors
David S. Hong (7 shared papers)Mitesh J. Borad (6 shared papers)Sinil Kim (5 shared papers)Jay Stoudemire (6 shared papers)Andrew Brenner (5 shared papers)Andreas G. Bader (5 shared papers)Yoon‐Koo Kang (3 shared papers)Muhammad S. Beg (1 shared paper)
Journals
Journal of Clinical Oncology (45 papers)Cancer Research (17 papers)Clinical Cancer Research (9 papers)Annals of Oncology (8 papers)European Journal of Cancer (6 papers)
Partner nations
United StatesUnited KingdomSpain

In The Last Decade

Jasgit C. Sachdev

126 papers receiving 3.6k citations

Jasgit C. Sachdev's Hit Papers

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors 2016 · 723 citations
7230+3+6Years since publication200400600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2016 Investigational New Drugs

Peers

Jasgit C. Sachdev
Comparison fields: 5 of 106
  • Cancer Research 871
  • Oncology 1.5k
  • Biomaterials 353
  • Molecular Biology 1.7k
  • Immunology 456
Replace David B. Darr with:
David B. Darr United States
N.V. Rajeshkumar United States
Laurie E. Littlepage United States
Jessalyn M. Ubellacker United States
Muralidhar Beeram United States
John Sarantopoulos United States
Kyoko Hida Japan
Pamela A. Trail United States
Emiliano Cocco United States
Ranjit S. Bindra United States
Jasgit C. Sachdev relative to David B. Darr United States David B. Darr's profile →
Citations per field
00.5×1.5×2×2.3×
David B. Darr · 1×
Citations per year

Countries citing papers authored by Jasgit C. Sachdev

Since Specialization
Citations

This map shows the geographic impact of Jasgit C. Sachdev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasgit C. Sachdev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasgit C. Sachdev more than expected).

Fields of papers citing papers by Jasgit C. Sachdev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasgit C. Sachdev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasgit C. Sachdev. The network helps show where Jasgit C. Sachdev may publish in the future.

Co-authors

The 25 scholars most cited alongside Jasgit C. Sachdev, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jasgit C. Sachdev Line = papers co-authored together Jasgit C. Sachdev links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Investigational New Drugs ·Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Mitesh J. Borad, Yoon‐Koo Kang, Jay Stoudemire, (unknown), Andreas G. Bader, Sinil Kim, David S. Hong
Hit paper breakdown →		2016723
2
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Cancer Discovery ·Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg
2017323
3
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Clinical Cancer Research ·Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Patrick A. Ott, Sarina A. Piha‐Paul, Philippe L. Bédard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
2018270
4
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Clinical Cancer Research ·Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev
2016235
5
AKT in cancer: new molecular insights and advances in drug development
British Journal of Clinical Pharmacology ·Prabhjot S. Mundi, Jasgit C. Sachdev, Carolyn K. McCourt, Kevin Kalinsky
2016220
6
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Clinical Cancer Research ·Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason E. Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald
2017145
7
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Clinical Cancer Research ·Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna P. Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevin J. Freise, Dimple Modi, Anjla Sood, Jessica E. Hutti, Johannes Wolff, Bert H. O’Neil
2019121
8
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Journal of Clinical Oncology ·Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, Gini F. Fleming, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Chapman‐Davis, Gerardo Colón‐Otero, Richard T. Penson, Ursula A. Matulonis, Young B. Kim, Kathleen N. Moore, Elizabeth M. Swisher, Bruce J. Dezube, Jing Y. Wang, Nathan Buerstatte, Sujata Arora, Pamela N. Münster
2018111
9
Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
Cancer Research ·HS Rugo, J.P. Delord, S-A. Im, P.A. Ott, SA Piha-Paul, PL Bedard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan
201680
10
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
British Journal of Cancer ·Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, Amita Patnaik, Drew Rasco, R. Donald Harvey, Patricia LoRusso, Jasgit C. Sachdev, Giovanni Abbadessa, Ronald E. Savage, Traci M. Tanaka Hall, Brian Schwartz, Y. Wang, Julia Kazakin, Walid L. Shaib
201780
11
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Clinical Cancer Research ·Michael L. Maitland, Jasgit C. Sachdev, Manish Sharma, Víctor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal J. Lakhani, Allison Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo
202169
12
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Journal of Clinical Oncology ·Johann S. de Bono, Lida A. Mina, Michael Gonzalez, Nicola J. Curtin, Evelyn Wang, Joshua W. Henshaw, Manpreet Chadha, Jasgit C. Sachdev, Daniela Matei, Gayle Jameson, Michael Ong, Bristi Basu, Zev A. Wainberg, Lauren A. Byers, Rashmi Chugh, Andrew Dorr, Stanley B. Kaye, Ramesh K. Ramanathan
201363
13
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
JAMA Oncology ·Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Peter J. O’Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
202062
14
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer
Breast Cancer Research and Treatment ·Gayle Jameson, Emanuel F. Petricoin, Jasgit C. Sachdev, Lance A. Liotta, David Loesch, Stephen P. Anthony, Manpreet Chadha, Julia Wulfkuhle, Rosa I. Gallagher, Kimberley A. Reeder, Mariaelena Pierobon, Monica Fulk, Nina Cantafio, Bryant Dunetz, William Mikrut, Daniel D. Von Hoff, Nicholas J. Robert
201459
15
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
British Journal of Clinical Pharmacology ·Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris A. de Jong, Apostolia M. Tsimberidou
202058
16
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Clinical Cancer Research ·Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Laurie A. Winter, Christine Reilly, Robert B. Parker, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer, Ramesh K. Ramanathan
201552
17
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
Breast Cancer Research and Treatment ·Jasgit C. Sachdev, Pamela N. Münster, Donald W. Northfelt, Hyo S. Han, X. Cynthia, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey K. Anders
202038
18
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg
201736
19
MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.
Journal of Clinical Oncology ·David S. Hong, Yoon‐Koo Kang, Andrew Brenner, Jasgit C. Sachdev, Samuel Ejadi, Mitesh J. Borad, Tae‐You Kim, Ho Yeong Lim, Keunchil Park, Carlos Becerra, Andreas G. Bader, Jay Stoudemire, (unknown), Sinil Kim, Muhammad Shaalan Beg
201632
20
Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.
Journal of Clinical Oncology ·Zev A. Wainberg, Saeed Rafii, Ramesh K. Ramanathan, Lida A. Mina, Lauren A. Byers, Rashmi Chugh, Jonathan W. Goldman, Jasgit C. Sachdev, Daniela Matei, Jennifer J. Wheler, Joshua W. Henshaw, Charlie Zhang, Gilles Gallant, Johann S. de Bono
201430

About Jasgit C. Sachdev

Jasgit C. Sachdev is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 129 papers that have together received 3.6k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (18 papers), Advanced Breast Cancer Therapies (16 papers), HER2/EGFR in Cancer Research (15 papers), PARP inhibition in cancer therapy (12 papers), Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). The work is most often cited by research in Cancer Research (871 citations), Oncology (1.5k citations), Biomaterials (353 citations), Molecular Biology (1.7k citations) and Immunology (456 citations). Jasgit C. Sachdev has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include David S. Hong, Mitesh J. Borad, Sinil Kim, Jay Stoudemire, Andrew Brenner, Andreas G. Bader, Yoon‐Koo Kang, Muhammad S. Beg, Ramesh K. Ramanathan and Carolyn K. McCourt. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David B. DarrBreakdown of academic impact, for papers by N.V. RajeshkumarBreakdown of academic impact, for papers by Laurie E. LittlepageBreakdown of academic impact, for papers by Jessalyn M. UbellackerBreakdown of academic impact, for papers by Muralidhar BeeramBreakdown of academic impact, for papers by John SarantopoulosBreakdown of academic impact, for papers by Kyoko HidaBreakdown of academic impact, for papers by Pamela A. TrailBreakdown of academic impact, for papers by Emiliano CoccoBreakdown of academic impact, for papers by Ranjit S. Bindra